For decades, the United States has led the world in developing life-saving medicines. That leadership has helped patients here and around the globe gain access to groundbreaking treatments.
That’s why I’m concerned about the growing push for policies like “Most Favored Nation” pricing. While the goal of lowering drug costs is important, tying American prices to foreign government systems could weaken the environment that has made innovation possible.
America should remain the global leader in medical discovery, not follow pricing policies set by other countries.
If lawmakers want to lower prescription costs for patients, there’s a more direct place to start. Pharmacy benefit managers negotiate significant discounts with drug manufacturers, but those savings too often never reach patients.
Congress recently began addressing PBM practices, and that work should continue. Requiring these middlemen to pass down the savings they negotiate would help patients without putting America’s leadership in medical innovation at risk.
Washington should keep its focus on PBM reform and making sure the system works for patients.
Mackenzie Kolk
